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Dear Editors,
We read with great interest the article by Sato et al., recently
published in Pediatric Nephrology, who presented a patient
with atypical Pneumocystis jiroveci pneumonia (PCP) with
multiple nodular granulomas after rituximab therapy for
refractory nephrotic syndrome [1]. We would like to present
a case of our patient who, interestingly, revealed a different
clinical course compared with that described by Sato and
colleagues.
An 11-year-old boy with steroid-dependent nephrotic
syndrome was on immunosuppression therapy for 9 years.
Renal biopsy revealed minimal-change nephrotic syndrome
(MCNS). In the course of the disease, he was treated
with steroids, cyclophosphamide, levamisole, mycophenolate
mofetil, and cyclosporine A (CsA). Because of the high
degree of steroid dependency and calcineurin–inhibitor
toxicity confirmed on renal biopsy, we decided to start
rituximab therapy (RTX). The first course of RTX treatment
consisted of two intravenous infusions of 375 mg/m2 given at
a weekly interval, with no short- or long-term side effects.
Simultaneously, prednisone and CsA at low doses was
continued. Six weeks after the first course of RTX, the patient
was admitted to our department because of fever 38° C, fatigue
even after minimal physical exercise, dyspnea, and tachycardia.
Physical examination revealed only stomatitis; laboratory tests
showed white blood cell count (WBC) 16.0 g/dl, C-reactive
protein (CRP) 10 mg/l, blood urea nitrogen (BUN) and
creatinine (Cr) within normal range, depletion of CD19 and
CD20 (i.e. <0.01 g/l), and decreased immunoglobulin G (IgG)
level. Standard blood and urine cultures were negative, as were
blood tests for Chlamydia andMycoplasma infections as well.
Polymerase chain reaction DNA (PCR-DNA) examination
excluded cytomegalovirus (CMV) and Epstein Barr virus
(EBV) infections. Diagnostic evaluation pointed toward
P. jiroveci and consisted of microscopy with staining of
an induced sputum specimen, which was negative. Both
chest X-ray and high-resolution computed tomography
(HRCT) were negative. Although antibiotic therapy with
IV azithromycin was started and CsA was tapered, after
7 days, his general condition deteriorated. Because of severe
dyspnea, oxygen therapy was initiated, and immunoglobulins
were administered. His poor clinical condition, stomatitis,
dyspnea, and positive Candida antigen mannan indicated a
fungal infection. Caspofungin therapy was started, with no
improvement. Due to progressing respiratory failure, the PCP
test was repeated (positive microscopy with staining of a
subepiglottal smear). Simultaneously, repeated chest HRCT
showed massive interstitial changes with crazy-paving and
extensive ground-glass patterns. Cotrimoxazole therapy with
120 mg/kg/24 h, i.e. 20 mg/kg/24 h of trimetoprim (TMP)
was started [2]. Within a few days of cotrimoxazole
introduction, a dramatic improvement in his general status
was observed. The therapy was continued for 21 days,
followed by a prophylactic dose of TMP: 5.0 mg/kg/day
administered orally in equally divided doses twice a day
on three consecutive days per week. After 4 weeks of
cotrimoxazole therapy, complete resolution of chest HRCT
changes was observed.
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The clinical course of PCP in immunocompromised
patients may vary widely: from subtle, almost asymptom-
atic, as described by Sato and colleagues, to respiratory
failure as seen in our patient. Moreover, radiographic
findings could be very different: unusual multiple nod-
ular changes in contrast to massive diffuse interstitial
pneumonia.
Summarizing, we observed gradual deterioration in the
general status of our patient, with escalating respiratory
failure and no changes in chest HRCT on admission. A
fungal infection was recognized, but its treatment did not
improve the clinical condition of the patient. We found that
negative microscopy with staining of a sputum specimen
absolutely does not exclude a PCP infection, and a
subepiglottal smear or bronchoscopy with bronchoalveolar
lavage should be performed. As did Sato and colleagues, we
propose initiating PCP prophylaxis at the beginning of RTX
protocol.
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